drugset / Trial / NCT00725231
Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP
Phase 3
Unknown
274 enrolled
University of Göttingen
German High-Grade Non-Hodgkin's Lymphoma Study Group · collabNordic Lymphoma Group · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Peripheral T cell lymphomas comprise 10-15% of all malignant lymphomas. The prognosis is significantly worse than that of aggressive B cell lymphomas. The prospects of elderly patients are especially poor, with an estimated disease free survival of only 25% after three years. Previous phase II trials have demonstrated a significant activity of the monoclonal anti CD52 antibody alemtuzumab in primary and relapsed T cell lymphoma. The investigators thus propose to investigate the value of adjuvant alemtuzumab in combination with dose dense CHOP-14 in patients with previously untreated peripheral T cell lymphoma.
Timeline
- Start
- 2008-02
- Primary completion
- 2014-03
- Completion
- 2014-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alemtuzumab | Monoclonal antibody | 30 mg | Subcutaneous |
| Background | Doxorubicin | Other / unclassified | — | — |
| Background | cylcophosphamide | Unknown | — | — |